Miles Wang, a researcher at OpenAI, is reportedly in discussions to launch a new startup focused on AI-driven drug discovery, with a valuation estimated at $2 billion, according to TechCrunch.
The proposed venture aims to leverage artificial intelligence to accelerate the development of new pharmaceuticals, reflecting growing interest in AI applications within the biotech sector.
For Japanese investors, this development highlights the increasing global momentum behind AI innovations in healthcare, a sector that is also seeing significant technological advances in Japan's domestic market.